Lkhoyaali S, Benhmida S, Ait Elhaj M, Layachi M, Bensouda Y, Errihani H
Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
Service d'oncologie médicale, institut national d'oncologie Moulay-Abdellah, rue Lamfadel-Cherkaoui Rabat Institut, BP 6527, 10000 Rabat, Maroc.
Pathol Biol (Paris). 2015 Feb;63(1):1-6. doi: 10.1016/j.patbio.2014.11.003. Epub 2014 Dec 30.
Thyroid cancer is an uncommon cancer. Molecular biology plays a vital role in its development. Chemotherapy showed unsatisfactory results in advanced stages where surgery and iodine therapy are not appropriate. These last ten years have been marked by a major advance in understanding the molecular features of this cancer and therapeutic correlations, moreover, clinical trials have focused on the treatment of this disease on metastatic stages and led to a significant therapeutic panel targeting angiogenesis, mutations frequently found in cervical cancer: RET, BRAF, RAS... these are the motesanib, axitinib, sunitinib, pazopanib, vandetanib, cabozotinib and sorafenib. The last three molecules have already the autorisation of FDA and EMA. In this review, we will put the item on oncogenetic characteristics of thyroid carcinoma as well as new targeted therapies in patients refractory to conventional treatment.
甲状腺癌是一种罕见的癌症。分子生物学在其发展过程中起着至关重要的作用。在手术和碘治疗不适用的晚期阶段，化疗效果并不理想。在过去十年里，人们对这种癌症的分子特征及其与治疗的相关性有了重大进展。此外，临床试验集中于转移性阶段该疾病的治疗，并产生了一系列针对血管生成、宫颈癌中常见突变（RET、BRAF、RAS等）的重要治疗药物：莫特沙尼、阿昔替尼、舒尼替尼、帕唑帕尼、凡德他尼、卡博替尼和索拉非尼。最后三种药物已获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）的批准。在本综述中，我们将阐述甲状腺癌的致癌特征以及针对传统治疗难治患者的新靶向治疗方法。
